

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/763,251	C	08/15/2001	Pascale Demil	B45150	4581
20462	7590	06/30/2003			
D.::11111		CHAM CORPOR	EXAMINER		
P. O. BOX 1	1539	LECTUAL PROPE	FOLEY, SHANON A		
KING OF P.	PRUSSIA, PA 19406-0939			ART UNIT	PAPER NUMBER
				1648	,
				DATE MAILED: 06/30/2003	Y

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
\$	09/763,251	DEMIL ET AL.
Office Action Summary	Examiner	Art Unit
	Shanon Foley	1648
The MAILING DATE of this communication app		
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a yeithin the statutory minimum of the will apply and will expire SIX (6) MG, cause the application to become	a reply be timely filed nirty (30) days will be considered timely. DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on <u>5 At</u>	nis action is non-final.	
, _		atters, presecution as to the morite is
3) Since this application is in condition for allows closed in accordance with the practice under		
Disposition of Claims		
4) Claim(s) 19-41 is/are pending in the application		
4a) Of the above claim(s) is/are withdraw	wn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		•
7) Claim(s) is/are objected to.		
 8) ☐ Claim(s) <u>19-41</u> are subject to restriction and/or Application Papers 	r election requirement.	
9) The specification is objected to by the Examine	.r	
10) The drawing(s) filed on is/are: a) accept		the Evaminer
Applicant may not request that any objection to the		
11) The proposed drawing correction filed on		•
If approved, corrected drawings are required in rep	•	
12) The oath or declaration is objected to by the Ex	-	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C	. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents	s have been received.	·
2. Certified copies of the priority documents	s have been received in	Application No
Copies of the certified copies of the prior application from the International Bu See the attached detailed Office action for a list	reau (PCT Rule 17.2(a))	
14) Acknowledgment is made of a claim for domesti	·	
· a) ☐ The translation of the foreign language pro	•	
15) Acknowledgment is made of a claim for domesti		
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)

Application/Control Number: 09/763,251

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 19-39, drawn to a vaccine composition comprising a *Salmonella typhi* polysaccharide Vi and one other antigen.

If applicant elects group I, applicant must also elect one or more of the following antigens:

- A) hepatitis A
- B) hepatitis B
- C) hepatitis E
- D) Dengue

Group II, claim(s) 40 and 41 drawn to a method of manufacturing a Vi polysaccharide.

The inventions listed as Groups I, II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of group I is a vaccine composition comprising a Salmonella typhi polysaccharide Vi and one other antigen. The special technical feature defining the first group lacks novelty in the art as evidenced by the teachings of Szu et al. (US 5,204,098). Szu et al. teach *S. typhi* Vi conjugated to proteins derived from diptheria, cholera and tetanus toxoids in a vaccine against typhoid fever, see column 1, lines 5-10, column 2, lines 43-55, column 5, lines 53-68, Table 1 in column 7, Table 3 in column 9 and column 12, lines 41-66. Since the special technical feature defining group I lacks novelty in the art, any subsequent group that does not have the special technical feature in common with the first group lacks unity of invention with the first group.

Groups A-D lack unity of invention with the first group because the different antigens are derived from distinctly different pathogens. The antigens do not share any structural or functional similarities with each other or with the Vi polysaccharide and the generic antigen defining the special technical feature of the first group.

Art Unit: 1648

Group II does not share unity of invention with the first group because the group is drawn to making a second product, a Vi polysaccharide. The method steps and the product made do not share the special technical feature of group I because the method does not include a generic second antigen that is required by the first group.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shanon Foley whose telephone number is (703) 308-3983. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4426 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Shanon Foloy June 28, 2003